Glimpure M1 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose utilization. The prolonged-release formulation ensures a gradual release of active ingredients, promoting sustained plasma concentration and improved patient compliance by reducing dosing frequency. Glimpure M1 Tablet PR is recommended as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is particularly beneficial for patients exhibiting insulin resistance and inadequate endogenous insulin secretion. Caution is advised in patients with renal or hepatic impairment, as metformin is contraindicated in severe renal dysfunction due to the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia primarily attributable to glimepiride. Regular monitoring of blood glucose levels, renal function, and patient adherence is essential to optimize therapeutic outcomes and minimize adverse events.

Dosage & How to Use